E-viri
PDF
Recenzirano
Odprti dostop
-
Mukku, Roy B, M.D; Fonarow, Gregg C, M.D; Watson, Karol E, M.D., Ph.D; Ajijola, Olujimi A, M.D., Ph.D; Depasquale, Eugene C, M.D; Nsair, Ali, M.D; Baas, Arnold S, M.D; Deng, Mario C, M.D; Yang, Eric H, M.D
Journal of cardiac failure, 06/2016, Letnik: 22, Številka: 6Journal Article
Highlights • The incidence of chemotherapy induced cardiomyopathy (CCMP) will rise with an increasing cancer survivor population. • Limited studies of beta blockers and angiotensin converting enzyme inhibitor agents have suggested benefit in CCMP. • Small studies have shown benefit of cardiac resynchronization therapy in CCMP who meet guideline based indications. • CCMP patients requiring left ventricular assist device therapy have a higher incidence of right ventricular dysfunction. • CCMP patients undergoing orthotopic heart transplantation have similar survival outcomes compared to other nonischemic controls.
